The treatment is approved for patients who have a moderate to high risk of recurrence, following nephrectomy or nephrectomy accompanied by surgical resection of metastatic lesions.
It is estimated that in 2022, 24,600 Canadians will be diagnosed with prostate cancer, and 4,600 Canadians will die from it. This represents 10% of male cancer deaths in the country.